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Background: Although pericardial effusion (PE) is not uncommon in patients with cancer, it may lead to cardiac
tamponade, a life-threatening condition. Prompt life-saving treatment is essential, and also allows the continuation
of the cancer treatment. The aim of this study was to determine the prognostic factors for survival in patients with
cancer who were treated surgically for PE.
Methods: We retrospectively reviewed the medical records of 55 patients with cancer with PE between January
2003 and October 2012, who were treated with a pericardial window operation. Overall survival (OS) was estimated
from the date of surgery, and patients were followed until the time of the final visit or time of death. Clinical
outcomes and candidate prognostic factors were analyzed.
Results: The median age of patients was 57 years (range 29 to 82 years), and 31 patients (56.4%) were male. The
most common primary malignancy was lung cancer (65.5%), followed by breast cancer (10.9%). Fifteen patients
(27.3%) developed recurrence of PE after surgery. The median OS duration was 4 months (range 0 to 39 months).
Multivariate analysis found that evidence of pericardial metastasis on preoperative imaging (P = 0.029) and
confirmation of malignant cells in the PE and/or pericardial tissue (P = 0.034) were associated with reduced OS.
Conclusion: Evidence of pericardial metastasis on preoperative imaging and cytopathologic confirmation that the
PE and/or pericardial tissue are positive for malignant cells can be used to predict poor clinical outcomes in
patients with cancer-related PE.
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Pericardial effusion (PE) associated with malignancy may
lead to cardiac tamponade, a life-threatening condition.
Lung cancer is the most common primary malignancy
associated with PE, followed by breast cancer and lymph-
oma [1,2]. Most patients complain of a gradual onset of fa-
tigue and shortness of breath [3]. Because of the gradual
onset of symptoms, which might be attributed to the
underlying malignancy, the diagnosis of malignant PE can
be missed or delayed. Although the survival of patients* Correspondence: ydkim@catholic.ac.kr
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unless otherwise stated.with malignant PE is known to be very short [4], optimal
treatments should be commenced immediately to relieve
symptoms, allow the continuation of systemic therapy for
the primary malignancy, and prevent unexpectedly early
death. Since 1829, when Larrey performed surgical drain-
age to treat PE through the subxiphoid approach [5],
various methods, including thoracotomy, video-assisted
thoracic surgery (VATS), and laparoscopic surgery, have
been used to treat PE associated with various conditions.
However, not all cancer-related PE is malignant PE, so
the differential diagnosis of cancer-related PE is difficult
[6]. In this study, we investigated patients who were
treated surgically for cancer-related PE, in order to iden-
tify prognostic factors affecting survival.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This retrospective study was approved by the institu-
tional review board of the College of Medicine, (Catholic
University of Korea). Between January 2003 and October
2012, 139 patients underwent pericardial window sur-
gery for PE associated with various conditions. Patients
with and patients without cancer who had PE associated
with transudate PE, tuberculosis, bacterial infection,
uremia, or autoimmune disease were excluded from this
study. Finally, we reviewed the medical records of 55 pa-
tients with clinically malignant PE who had undergone
surgical management because of cancer-related PE.
Preoperative assessments included chest computed
tomography (CT) and two-dimensional (2-D) and Doppler
echocardiography. The definition of cardiac tamponade
was based on the following criteria [7]: right atrial and ven-
tricular collapse and greater than 25% respiratory variation
in mitral inflow. Pericardial metastasis was defined as peri-
cardial nodules, pericardial thickening, or diffuse enhance-
ment of the pericardium on preoperative CT after contrast
injection (Figure 1) [8]. The demographic and clinical data
of patients and cytopathologic and histopathologic data
from the surgical specimens were collected for analysis.
Statistical analysis
All statistical analyses were carried out using SPSS soft-
ware (v18l IBM Corporation). Continuous variables were
compared using the Kruskal-Wallis test, and categorical
variables were compared using the χ2 test. Overall survival
(OS) was analyzed using the Cox proportional hazards
model; before application of this model, the proportionality
assumption was checked. Multivariate analysis for OS was
also performed using the Cox proportional hazards model.
Variables with P < 0.05 by univariate analysis were ultim-
ately evaluated by multivariate analysis. P < 0.05 was con-
sidered statistically significant in multivariate analysis.Figure 1 Computed tomography finding suspicious of pericardial me
nodularity (arrow).Results
The characteristics of the study patients are shown in
Table 1. The median age of patients was 57 years (range
29 to 82 years) and 31 patients (56.4%) were male. The
primary malignancy was lung cancer in 36 patients;
breast cancer in 6; gastrointestinal cancer in 5; hematologic
malignancy in 4; and thyroid cancer, ovarian cancer, thym-
oma, and cardiac sarcoma in 1 patient each. Seven (12.7%)
patients were diagnosed with PE at the time of diagnosis of
the primary cancer, and the others were diagnosed during
chemotherapy for advanced primary cancer. The median
time interval between the diagnosis of cancer and PE was
9 months (range 0 to 180 months). Fifteen patients under-
went pericardiocentesis before operation, and of these,
eight developed recurrent PE. Evidence of pericardial me-
tastasis on the preoperative CT scan was seen in 20 pa-
tients (36.4%). The sensitivity and specificity of CT for the
diagnosis of malignant PE (compared with cytopathologic
analysis of PE or pericardial tissue) was 35.3% and 61.9%,
respectively.
Three different approaches were used for pericardial
window surgery: mini-thoracotomy for 14 patients (25.5%),
the subxiphoid approach for 16 (29.1%), and VATS for 25
(45.5%. The median anesthesia time was 80 minutes (range
30 to 180 minutes), and the median amount of drainage
was 500 ml (range 100 to 1500). Cytopathologic examin-
ation of pericardial fluid and pericardial tissue confirmed
malignancy in 34 patients (61.8%).
There were two postoperative deaths (3.6%). One patient
developed active bleeding after pericardiocentesis, and des-
pite emergent pericardial window surgery to control the
bleeding, he died of acute renal failure and hypoxic brain
damage on postoperative day 5. The second patient devel-
oped pneumonia after surgery and died of sepsis.
There were seven (12.7%) patients with operative
morbidity, which included atrial fibrillation, prolongedtastasis. (a) Pericardial wall thickening (arrow) and (b) pericardial
Table 1 Characteristics of 55 patients with pericardial
effusion treated by surgerya
Variables Value













Time to PE after cancer diagnosis. months 9 (0 to 180)








Cardiac tamponade, n (%) 28 (50.9)
Ejection fraction, (%) 62% (48 to 75)
Prior pericardiocentesis, n (%) 15 (27.3)
Recurrence after pericardiocentesis, n 8
Maximum distance of pericardial space by CT, mm 32.25 (11.7 to 54.68)
Concomitant pleural effusion, n (%) 39 (70.9)
Mediastinal lymphadenopathy, n (%) 40 (72.7)
Prior radiotherapy of the chest, n (%) 22 (40)
Pericardial metastasis by CT, n (%) 20 (36.4)
Pulmonary thromboembolism, n (%) 3 (5.5)
Extrathoracic metastasis, n (%) 32 (58.2)
APC, Atrial premature contraction; CT, Computed tomography; GI,
Gastrointestinal; PE, Pericardial effusion.
aData are presented as median (range) unless otherwise stated.
Table 2 Operative and postoperative dataa
Variables Value
Operative procedure, n (%)
VATS 25 (46)
Mini-thoracotomy 14 (25)
Subxiphoid approach 16 (29)
Operative time, min 80 (30 to 180)
Volume of drainage fluid, ml 500 (100 to 1500)
Nature of pericardial fluid, n (%)
Serous 18 (32.7)
Sanguineous 37 (67.3)
Malignant cells on cytopathology n (%) 34 (61.8)
Adjuvant chemotherapy after operation, n (%) 51 (92.7)
Death, n (%) 2 (3.6)
Complications, n (%) 7 (12.7)
Acute renal failure, n 1
Pneumonia, n 1
Atrial fibrillation, n 1
Prolonged ventilation, n 1
Cardiogenic shock, n 1
Constrictive pericarditis, n 2
Recurrence, n (%) 15 (27.3)
VATS, video-assisted thoracic surgery.
aData are presented as median (range) unless otherwise stated.
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strictive pericarditis (Table 2).
Fifteen patients (27.3%) developed recurrent PE after
surgery. Ten patients (66.7%) with pathologically malig-
nant PE and 6 patients (40%) with pericardial metastasis
on preoperative CT showed recurrent PE. During the
follow-up period, 45 (81.8%) patients died because of
progression of their malignancy. The median survivaltime was 4 months (range 0 to 39 months), and the
1-year survival rate was 21.8%. There were no significant
differences in the rate of postoperative complications and
recurrence between the different surgical approaches.
However, the anesthesia time was significantly longer for
the patients undergoing VATS, compared with the other
procedures (P = 0.046).
In survival analyses, no affect on OS was seen for age;
gender; type of primary malignancy; disease-free interval
between the diagnosis of cancer and occurrence of PE;
abnormal electrocardiogram; presence of cardiac tam-
ponade; mediastinal lymphadenopathy, pleural effusion,
or extrathoracic metastasis; or surgical approach. Evidence
of pericardial metastasis on preoperative CT (P = 0.029)
and malignant PE found on postoperative cytopathologic
examination (P = 0.034) were associated with poor OS by
both univariate and multivariate analysis (Table 3). The
median OS times of patients with and without evidence of
pericardial metastasis on preoperative CT were 4 and
5 months, respectively. The median OS times of patients
with and without cytopathologic confirmation of malignant
PE were 2 and 8 months, respectively (Figure 2). Patients
negative for both pericardial metastasis on preoperative
CT and cytopathologic maliganancy had better clinical out-
comes compared with positive for either (Figure 3).
Table 3 Univariate and multivariate analysis for overall survival
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Lung cancer 1.153 0.623 to 2.136 0.651 – – –
Adenocarcinoma 1.128 0.623 to 2.042 0.691 – – –
Interval between diagnoses of PE and primary cancer 0.994 0.981 to 1.007 0.384 – – –
Mediastinal lymphadenopathy 1.456 0.735 to 2.884 0.281 – – –
Pericardial metastasis on CT 2.224 1.148 to 4.306 0.018 2.078 1.077 to 4.012 0.029
Extrathoracic metastasis 1.818 0.980 to 3.373 0.058 – – –
Abnormal EKG 1.730 0.935 to 3.201 0.081 – – –
Cytopathologic malignant PE 2.079 1.114 to 3.878 0.021 1.964 1.053 to 3.663 0.034
PE, pericardial effusion, CT, computed tomography.
Cytopathologically malignant PE included positive PE and/or positive pericardial tissue.
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PE is a not uncommon condition. Its etiologies include
uremia, malignancy, infection, and autoimmune disease
[9]. The clinical presentation at the time of diagnosis
varies, because PE generally develops gradually. How-
ever, PE in patients with cancer often has an acute onset
and may be life-threatening (that is, cardiac tamponade).
The mechanisms of PE associated with malignancy in-
clude metastasis to the pericardium, obstruction of lymph-
atic drainage, and induction by drugs or radiation = d [10].
Several studies [4,11,12] have shown that patients with
cancer who developed PE had worse clinical outcomes
than other patients with PE, with median survival times
ranging from 3.7 to 6 months and 1-year survival rates
from 13.8% to 20%. The results are similar to our findings
of a median survival time of 4 months and a 1-year sur-
vival rate of 21.8%.
Although the prognosis of malignant PE is not good,
ongoing treatment is sometimes necessary. The goal of
treatment is sufficient drainage of the pericardial fluid
to relieve the symptomsand prevention of recurrence.Figure 2 Overall survival (OS) of patients with cancer-related pericard
pericardial metastasis on preoperative imaging. Solid line: evidence of peric
metastasis (n = 35). (b) OS according to cytopathologic confirmation of ma
confirmation (n = 21).Pericardiocentesis is an easier and less invasive procedure
than pericardial window surgery, allowing prompt treat-
ment at the time of diagnosis. However, pericardiocentesis
has a recurrence rate of up to 20% at 30 days [13], which is
higher than recurrence after surgical drainage (1-10% of re-
currence) [4,13,14]. In addition, pericardiocentesis may
lead to severe complications, such as severe bleeding and
cardiac arrest, as was seen in one of our patients who died
of his complications.
Surgical drainage is also used for PE, because it is effect-
ive and has a low recurrence rate. Since Larrey performed
the subxiphoid approach in 1829 [5], various surgical tech-
niques have been used; however, there is no consensus on
the best procedure. Subxiphoid pericardiostomy is very
simple and safe because it can be performed under direct
visualization and under local anesthesia [9]. The disadvan-
tage of this procedure is that pericardial resection is too
limited to provide biopsy tissue. Some surgeons prefer the
transthoracic approach to the subxiphoid, because it pro-
vides better exposure and allows more pericardial resection
and natural drainage of effusate to the pleural cavity.ial effusion. (a) Overall survival (OS) according to evidence of
ardial metastasis (n = 20); dashed line: no evidence of pericardial
lignancy. Solid line, confirmation (n = 34); dashed line, no
Figure 3 Overall survival (OS) according to presence of cytopathologically malignant pericardial effusion (PE) or pericardial metastasis
by computed tomography (CT). Patients negative for both pericardial metastasis on CT and cytopathologic malignancy had better clinical
outcomes. CT (+), pericardial metastasis on CT scan; pathology (+), cytopathologic malignant PE.
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tions after thoracotomy [15], methods such as mini-
thoracotomy and VATS have been introduced. Pericar-
dial window surgery using mini-thoracotomy is a rapid
and simple technique [16], and results in less postopera-
tive pain and decreased immune response compared
with conventional thoracotomy. Celik et al. reported on
48 patients with malignant PE who were treated using
mini-thoracotomy [17]. The recurrence rate was only
2.08%, and the 30-day mortality rate was 8.33%. VATS is
also minimally invasive surgery, which results in de-
creased pain and shortened recovery time, and allows
more precision because of the magnified field of view
[18]. However, VATS require single-lung ventilation, which
some patients cannot tolerate. Although comparing the
outcomes of the different surgical approaches was difficult
because of the heterogeneity of our study patients, there
were no significant differences seen for rates of complica-
tion or recurrence.
The differential diagnosis between benign and malig-
nant PE is often difficult, and the diagnostic criteria for
preoperative imaging of malignant PE have not yet been
established. Sun et al. [19] suggested that irregular peri-
cardial thickening with PE on CT was highly specific
(97.8%) for pericardial metastasis, although the sensitivity
(35.7%) was low. We evaluated the diagnostic characteris-
tics of preoperative CT used for pericardial metastasis.Although the sensitivity and specificity of positive CT find-
ings were low (35.3% and 61.9%, respectively), positive pre-
operative CT findings were associated with shorter survival
times (Figure 2a).
Considering the high rate of complications and recur-
rence in our study, less invasive and well-tolerated pro-
cedures may be needed compared with surgical procedures
in patients with PE. Ruiz-Garcia et al. reported on the use
of percutaneous balloon pericardiotomy for the maliganant
PE and its effectiveness and safety [20].
There have been several studies to identify the prog-
nostic factors of cancer-related PE. One study found that
the sensitivity of pericardial fluid analysis/pericardial bi-
opsy for malignant PE was relatively low compared with
that of pericardoscopy (75% and 65%, respectively) and
negative results for malignancy of the pericardial fluid
and tissue does not mean that PE is non-malignant in
patients with cancer [21], so the prognostic roles of peri-
cardial fluid analysis and biopsy are controversial. Wang
et al. [6] reported that in 60 of 88 patients (68%) with
PE-associated non-small cell lung cancer, the pericardial
fluid cytology was positive for malignant cells; however,
this was not significantly associated with OS. Cullinane
et al. [3] reported similar results: of 63 patients with
cancer, 28 (44%) and 15 (24%) were diagnosed with ma-
lignant PE by pericardial fluid cytology and pericardial
biopsy, respectively. There was no significant difference
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and those diagnosed by biopsy tissue. By contrast, Celik
et al. [17] reported that in a group of patients with can-
cer, those with malignant PE had worse clinical out-
comes than those with non-malignant PE. Of 48 patients
with cancer, 26 (54.1%) developed malignant PE. The
mean survival time of patients with and without malig-
nant PE was estimated to be 11.9 and 18.4 months,
respectively (P = 0.004). Gornik et al. investigated 269
patients who had undergone pericardiocentesis for PE,
and found that 96 patients had PE-associated malig-
nancy. For these patients, median survival times were
7.3 and 19.7 weeks for patients with and without abnor-
mal cytology, respectively (P = 0.0221) [22]. In our study,
we found that presence of pericardial metastasis on pre-
operative CT scans and cytopathologic confirmation of
malignant PE were both associated with worse clinical
outcomes in multivariate analysis. Furthermore, the pa-
tients with cancer without pericardial metastasis on
preoperative CT and cytopathologic malignancy had pro-
longed survival. Although the differential diagnosis of
cancer-related PE is difficult, it could be possible to pre-
dict prognosis using preoperative CT and cytopathologic
confirmation.
Our study has some limitations. It was retrospective
study with a small and heterogeneous sample size.
Conclusions
Surgical treatment of malignant PE is crucial for symp-
tomatic control and precise diagnosis. In the current
study, none of the surgical approaches used was found
to be superior to the others, therefore, the type of pro-
cedure should be based on the individual patient. In
addition, presences f pericardial metastasis on preopera-
tive CT and cytopathologic confirmation of malignant
PE may be associated with worse clinical outcome.
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